Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy
Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy
复制标题
DOI：
10.1016/j.biomaterials.2011.08.014
复制
发表时间：
2011-12-01
期刊：
影响因子：
14
通讯作者：
Chuang, Cheng-Keng
中科院分区：
文献类型：
--
作者：
Hua, Mu-Yi;Yang, Hung-Wei;Chuang, Cheng-Keng
包括磁性Fe 3 O 4（SHMNP）核和水性稳定的自掺杂聚[N-（1-酮-丁酸）]苯胺（SPAnH）壳，其具有高的阿霉素（DOX）载药量（类似于27.1wt%）。SHMNCs显示出超顺磁性，其磁化强度为89.7 emu/g，大于Resovist（一种用于磁共振成像的商业造影剂; 73.7 emu/g）。将抗癌药物DOX结合到这些纳米载体上增强了药物的热稳定性，并使其通过磁靶向（MT）疗法递送到MGH-U1膀胱癌细胞的效率最大化，部分地通过避免P-糖蛋白（P-gp）泵的作用来提高DOX的细胞内浓度。（434.7 mM（-1）s（-1））的SHMNCs不仅是化疗药物最有效的MT载体，而且是MRI的优良造影剂，允许评估DOX在各种组织和器官中的分布和浓度。这种先进的药物递送系统有望使用较低的治疗剂量提供更有效的MT治疗和肿瘤治疗，并可能减少DOX引起的心脏毒性的副作用。(C)2011爱思唯尔有限公司保留所有权利。
comprised of a magnetic Fe3O4 (SHMNPs) core and a shell of aqueous stable self-doped poly[N-(1-one-butyric acid)]aniline (SPAnH), which have a high drug loading capacity (similar to 27.1 wt%) of doxorubicin (DOX). The SHMNCs display superparamagnetic property with a magnetization of 89.7 emu/g greater than that of Resovist (a commercial contrast agent used for magnetic resonance imaging; 73.7 emu/g). Conjugating the anticancer drug DOX to these nanocarriers enhances the drug's thermal stability and maximizes the efficiency with which it is delivered by magnetic targeting (MT) therapy to MGH-U1 bladder cancer cells, in part by avoiding the effects of p-glycoprotein (P-gp) pumps to enhance the intracellular concentration of DOX The high R2 relaxivity (434.7 mM(-1)s(-1)) of SHMNCs not only be a most effective MT carrier of chemotherapeutic agent but be an excellent contrast agent of MRI, allowing the assessment of the distribution and concentration of DOX in various tissues and organs. This advanced drug delivery system promises to provide more effective MT therapy and tumor treatment using lower therapeutic doses and potentially reducing the side effects of cardiotoxicity caused by DOX. (C) 2011 Elsevier Ltd. All rights reserved.